Table 1 Characteristics of the included studies for the meta-analysis
First author | Year of publication | Patients (n) | Metastatic status | WHO histological type | AJCC stage | Cutoff value | Endpoints | Median follow-up (months) | Age (years) | Treatment | NOS score |
|---|---|---|---|---|---|---|---|---|---|---|---|
Jiang | 2017 | 327 | Mixed | NA | I-IV (7th) | 403.00 | OS | 38.3 (2–164.6) | 50 (20–80) | Radiotherapy +/− chemotherapy | 7 |
Oei | 2018 | 585 | Mixed | II/III | I-IV (7th) | 527.20 | OS/PFS/DMFS | 63.3 (4.8–86.4) | 49 (17–82) | IMRT | 8 |
Lin | 2019 | 243 | Metastatic | I/II/III | NA | 930.00 | OS/PFS | 77 (2–135) | 48 (17–81) | Radiotherapy +/− chemotherapy | 8 |
Feng | 2020 | 417 | Metastatic | NA | III-IV (8th) | 488.90 | OS/PFS | NA | 47 (14–81) | Radiotherapy +/− chemotherapy | 8 |
Zeng | 2020 | 255 | Mixed | I/II/III | I-IV (7th) | 715.74 | OS | 33.5 (2.1–151.2) | 51 (12–78) | Radiotherapy +/− chemotherapy, chemotherapy, untreated | 6 |
Li | 2021 | 342 | Mixed | NA | I-IV (8th) | 804.08 | OS/PFS | 66 (3–110) | 49 (16-83) | IMRT, CCRT +/− induction, and/ or adjuvant chemotherapy | 7 |